Deciphering the Antimicrobial Potential of Taxus wallichiana Zucc: Identification and Characterization Using Bioassay-Guided Fractionation
Chem Biodivers. 2022 Dec 27:e202200572. doi: 10.1002/cbdv.202200572. Online ahead of print.ABSTRACTTaxus wallichiana Zucc. is a high valued medicinal plant and has been mainly studied for its anti-cancer properties. However, research on its other important biological activities, such as its antimicrobial potential, still needs attention. The focus of the present study is to investigate the antimicrobial activity of secondary metabolites of T. wallichiana needles against 3 different groups of microorganisms, i. e., bacteria, actinobacteria, and fungi. Bioactive compounds from T. wallichiana needles were separated through co...
Source: Chemistry and Biodiversity - December 27, 2022 Category: Biochemistry Authors: Priyanka Adhikari Vasudha Agnihotri Sunil Kumar Suman Anita Pandey Source Type: research
Oral propranolol and topical timolol in the treatment of post ‐burn pyogenic granuloma: Two cases and a review of the literature
Pyogenic granuloma (PG) is an uncommon complication of burned skin; most treatments are supportive or invasive. In our study, using beta-blockers, oral and topical form, to treat post-burn PG as a type of hemangioma were effective and safe. AbstractTwo cases of pyogenic granulomas in burned skin were presented, a 17-month-old boy and a 7-year-old girl, being given oral propranolol and topical timolol. Both cases showed lesions improvement with no adverse effects, suggesting that beta-blocker therapy may have a positive impact on the treatment of pyogenic granuloma after burns. (Source: Clinical Case Reports)
Source: Clinical Case Reports - November 24, 2022 Category: General Medicine Authors: Zahra Ebrahimi,
Zeinab Mahdi,
Ali Asghar Khairi,
Elham Behrangi,
Armaghan Gharehaghaji Zare,
Abbas Dehghani,
Azadeh Goodarzi Tags: CASE REPORT Source Type: research
Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial
CONCLUSION: Although the topical formulation of timolol, 0.5% (w/w), was found to reduce the average maximum grade of ARD and increase the mean (SD) time of initial RID occurrence, it showed no effect on ARD, severity, and QOL. However, future clinical trials should be performed to assess timolol gel formulation in larger study populations.TRIAL REGISTRATION: https://irct.ir/ IRCT20190810044500N11 (17/03/2021).PMID:36266613 | DOI:10.1186/s12885-022-10064-x (Source: Cancer Control)
Source: Cancer Control - October 20, 2022 Category: Cancer & Oncology Authors: Mohsen Nabi-Meybodi Adeleh Sahebnasagh Zahra Hakimi Masoud Shabani Ali Asghar Shakeri Fatemeh Saghafi Source Type: research
Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial
Radiation therapy is one of the standard methods in the treatment of breast cancer. Radiotherapy-induced dermatitis (RID) is a common complication of radiotherapy (RT) resulting in less tolerance in RT and eve... (Source: BMC Cancer)
Source: BMC Cancer - October 20, 2022 Category: Cancer & Oncology Authors: Mohsen Nabi-Meybodi, Adeleh Sahebnasagh, Zahra Hakimi, Masoud Shabani, Ali Asghar Shakeri and Fatemeh Saghafi Tags: Research Source Type: research
Successful Late Treatment of Orbital Infantile Haemangiomas in Two Teenagers with Topical Transcutaneous Timolol Maleate 0.5% Alone
Klin Monbl Augenheilkd. 2022 Oct;239(10):1221-1231. doi: 10.1055/a-1936-3531. Epub 2022 Oct 18.ABSTRACTWe previously described the first successful treatment of deep periocular and, subsequently, orbital infantile haemangiomas (IH) with topical transcutaneous timolol maleate 0.5% (TM 0.5%) alone as the first-line treatment in the acute proliferative phase in infancy. It is not known whether orbital IH with persistent proptosis in later years, untreated in infancy, would still respond to TM 0.5% treatment as well. To our best knowledge, we here present the first reports of the successful late treatment of persistent orbital...
Source: Klinische Monatsblatter fur Augenheilkunde - October 18, 2022 Category: Opthalmology Authors: G öran Darius Hildebrand Zuzana Sipkova Source Type: research
Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open angle glaucoma and ocular hypertension management: a focus on efficacy, safety and tolerability
Expert Opin Drug Saf. 2022 Oct 17. doi: 10.1080/14740338.2022.2135701. Online ahead of print.ABSTRACTINTRODUCTION: Elevated intraocular pressure (IOP) is the most important modifiable risk factor for irreversible sight loss in open angle glaucoma (OAG). The topical fixed-dose combination (FC) of preservative-free (PF) tafluprost (0.0015%) and timolol (0.5%) (tafluprost/timolol) is among the second-line IOP-lowering options for OAG and ocular hypertension (OHT).AREAS COVERED: PubMed searches identified publications reporting key evidence from randomized controlled trials (RCTs) and real-world studies examining the safety, t...
Source: Expert Opinion on Drug Safety - October 17, 2022 Category: Drugs & Pharmacology Authors: Francesco Oddone Source Type: research
Good Clinical Responders to Topical Timolol in Patients with Infantile Hemangiomas: A 7-Year Retrospective Study of 328 Korean Patients
CONCLUSION: This study demonstrated that topical timolol treatment was an effective and well-tolerated treatment for IHs. Physicians are encouraged to consider several patient- or lesional factors that might affect treatment response to achieve better clinical outcomes.PMID:36198627 | DOI:10.5021/ad.21.203 (Source: Annals of Dermatology)
Source: Annals of Dermatology - October 5, 2022 Category: Dermatology Authors: Da-Ae Yu Se Hee Min Jaeryong Song Jong Seo Park Hanjae Lee Jungyoon Ohn Kyu Han Kim Source Type: research
